Dynamics in the choice of treatment for patients with Multiple Myeloma – Results from the MYRIAM registry. 10. Juli 2020 Engelhardt, M., Knauf, W., Lipke, J., Reiser, M., Dörfel, S., Kortüm, M., Schlag, R., von der Heyde, E., La Rosée, P., Pfannes, R., Lamberti, C., Houet, L., Medinger, T., Jänicke, M., Marschner, N., Dechow, T., Einsele, H., 2020. HemaSphere 4(S1)(EP994), 454–455. Effectiveness and Tolerability of Nab-Paclitaxel in Younger versus Elderly Patients With Metastatic HR-Positive/HER2-Negative Breast Cancer: Results From the Noninterventional, Prospective Study NABUCCO Potthoff, Karin, Oliver Stötzer, Ulrike Söling, Richard Hansen, Johanna Harde, Stephanie Dille, Arnd Nusch, und Norbert Marschner, 2020. Clinical Breast Cancer 20, Nr. 3 (1. Weiterlesen Real-world effectiveness of nab-paclitaxel plus carboplatin as first-line therapy for patients with advanced NSCLC: Results of the second interim analysis of the NEPTUN study. Dechow T, Riera-Knorrenschild J, Hackanson B, Fischer von Weikersthal L, Schulz H, Chiabudini M, Timm B, Zerbes R, Potthoff K, 2020. J Clin Oncol 38:… Weiterlesen